Generation of recombinant canine interleukin-15 and evaluation of its effects on the proliferation and function of canine NK cells

Veterinary Immunology and Immunopathology

Volumn 165, Issue 1-2, 2015, Pages 1-13

  Lee, Soo Hyeon ^a   Shin, Dong Jun ^a   Kim, Sang Ki ^a  

^a Kongju National University   (South Korea)

Author keywords

Canine; Immunotherapy; Interleukin 15; NK cells; Recombinant protein

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; MESSENGER RNA; PERFORIN; POLYHISTIDINE TAG; RECOMBINANT CANINE INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 15; UNCLASSIFIED DRUG; INTERLEUKIN 15; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BEAGLE; BLOOD SAMPLING; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FLOW CYTOMETRY; LYMPHOCYTE; MALE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CHEMISTRY; DOG; DRUG EFFECTS; HUMAN; LEUKOCYTE COUNT; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS; THYROID NEOPLASMS; TUMOR CELL LINE; VETERINARY;

CANIS FAMILIARIS;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOGS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 84928760674     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2015.04.002     Document Type: Article

References (46)

1. Anderson D.M., Johnson L., Glaccum M.B., Copeland N.G., Gilbert D.J., Jenkins N.A., Valentine V., Kirstein M.N., Shapiro D.N., Morris S.W. Chromosomal assignment and genomic structure of Il15. Genomics 1995, 25:701-706.
2. Bamford R.N., DeFilippis A.P., Azimi N., Kurys G., Waldmann T.A. The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J. Immunol. 1998, 160:4418-4426.
3. Berger C., Berger M., Hackman R.C., Gough M., Elliott C., Jensen M.C., Riddell S.R. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009, 114:2417-2426.
4. Budagian V., Bulanova E., Paus R., Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006, 17:259-280.
5. Chou P.C., Chuang T.F., Jan T.R., Gion H.C., Huang Y.C., Lei H.J., Chen W.Y., Chu R.M. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles. Vet. Immunol. Immunopathol. 2009, 130:25-34.
6. Chuang T.F., Lee S.C., Liao K.W., Hsiao Y.W., Lo C.H., Chiang B.L., Lin X.Z., Tao M.H., Chu R.M. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int. J. Cancer 2009, 125:698-707.
7. Cornish G.H., Sinclair L.V., Cantrell D.A. Differential regulation of T-cell growth by IL-2 and IL-15. Blood 2006, 108:600-608.
8. Dale D.C., Nichol J.L., Rich D.A., Best D.M., Slichter S.J., Sheridan W., Hunt P. Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand. Blood 1997, 90:3456-3461.
9. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15Rα recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
10. Fehniger T.A., Caligiuri M.A. Interleukin 15: biology and relevance to human disease. Blood 2001, 97:14-32.
11. Gaggero A., Azzarone B., Andrei C., Mishal Z., Meazza R., Zappia E., Rubartelli A., Ferrini S. Differential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms. Eur. J. Immunol. 1999, 29:1265-1274.
12. Grabstein K.H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., Beers C., Richardson J., Schoenborn M.A., Ahdieh M. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994, 264:965-968.
13. Hsiao Y.W., Liao K.W., Chung T.F., Liu C.H., Hsu C.D., Chu R.M. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol. Immunother. 2008, 57:1091-1104.
14. Huang Y.C., Hung S.W., Jan T.R., Liao K.W., Cheng C.H., Wang Y.S., Chu R.M. CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J. Leukoc. Biol. 2008, 84:1501-1510.
15. Imada K., Bloom E.T., Nakajima H., Horvath-Arcidiacono J.A., Udy G.B., Davey H.W., Leonard W.J. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J. Exp. Med. 1998, 188:2067-2074.
16. Jakobisiak M., Golab J., Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 2011, 22:99-108.
17. Kelly J., Spolski R., Imada K., Bollenbacher J., Lee S., Leonard W.J. A role for Stat5 in CD8+ T cell homeostasis. J. Immunol. 2003, 170:210-217.
18. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., Matsuki N., Charrier K., Sedger L., Willis C.R. Reversible defects in natural killer and memory CD8T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000, 191:771-780.
19. Knapp D.W., Leibnitz R.R., DeNicola D.B., Turek J.J., Teclaw R., Shaffer L., Chan T.C. Measurement of NK activity in effector cells purified from canine peripheral lymphocytes. Vet. Immunol. Immunopathol. 1993, 35:239-251.
20. Kurys G., Tagaya Y., Bamford R., Hanover J.A., Waldmann T.A. The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15. J. Biol. Chem. 2000, 275:30653-30659.
21. Lin C.-Y., Chuang T.-F., Liao K.-W., Huang Y.-J., Pai C.-C., Chu R.-M. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett. 2008, 272:285-295.
22. Lin J.-X., Migone T.-S., Tseng M., Friedmann M., Weatherbee J.A., Zhou L., Yamauchi A., Bloom E.T., Mietz J., John S. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995, 2:331-339.
23. Lin Y.C., Huang Y.C., Wang Y.S., Juang R.H., Liao K.W., Chu R.M. Canine CD8T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules. Vet. Immunol. Immunopathol. 2010, 133:144-153.
24. Loughran T.P., Deeg H.J., Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. Cell. Immunol. 1985, 95:207-217.
25. Lugli E., Goldman C.K., Perera L.P., Smedley J., Pung R., Yovandich J.L., Creekmore S.P., Waldmann T.A., Roederer M. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood 2010, 116:3238-3248.
26. Marks-Konczalik J., Dubois S., Losi J.M., Sabzevari H., Yamada N., Feigenbaum L., Waldmann T.A., Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11445-11450.
27. Meazza R., Azzarone B., Orengo A.M., Ferrini S. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. BioMed Res. Int. 2011, 2011.
28. Michael H.T., Ito D., McCullar V., Zhang B., Miller J.S., Modiano J.F. Isolation and characterization of canine natural killer cells. Vet. Immunol. Immunopathol. 2013, 155:211-217.
29. Miller J.S., Rooney C.M., Curtsinger J., McElmurry R., McCullar V., Verneris M.R., Lapteva N., McKenna D., Wagner J.E., Blazar B.R., Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol. Blood Marrow Transplant. 2014, 20:1252-1257.
30. Miyazaki T., Kawahara A., Fujii H., Nakagawa Y., Minami Y., Liu Z.-J., Oishi I., Silvennoinen O., Witthuhn B.A., Ihle J.N. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994, 266:1045-1047.
31. Mueller Y.M., Petrovas C., Bojczuk P.M., Dimitriou I.D., Beer B., Silvera P., Villinger F., Cairns J.S., Gracely E.J., Lewis M.G. Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques. J. Virol. 2005, 79:4877-4885.
32. Munger W., Dejoy S.Q., Jeyaseelan R., Torley L.W., Grabstein K.H., Eisenmann J., Paxton R., Cox T., Wick M.M., Kerwar S. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol. 1995, 165:289-293.
33. Nakada Y., Tokumitu K., Kosaka T., Kuwabara M., Tanaka S., Koide F. Correlation between canine NK cell mediated cytotoxicity and radical production. Vet. Immunol. Immunopathol. 1995, 45:285-295.
34. Onu A., Pohl T., Krause H., Bulfone-Paus S. Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J. Immunol. 1997, 158:255-262.
35. Park Y.-K., Shin D.-J., Cho D., Kim S.-K., Lee J.-J., Shin M.-G., Ryang D.-W., Lee J.-S., Park M.-H., Yoon J.H. Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells. Anticancer Res. 2012, 32:839-846.
36. Pillet A.H., Bugault F., Theze J., Chakrabarti L.A., Rose T. A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J. Immunol. 2009, 182:6267-6277.
37. Ranson T., Vosshenrich C.A., Corcuff E., Richard O., Müller W., Di Santo J.P. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003, 101:4887-4893.
38. Ringler S.S., Krakowka S. Cell surface markers of the canine natural killer (NK) cell. Vet. Immunol. Immunopathol. 1985, 9:1-11.
39. Rodella L., Zamai L., Rezzani R., Artico M., Peri G., Falconi M., Facchini A., Pelusi G., Vitale M. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br. J. Haematol. 2001, 115:442-450.
40. Romee R., Leong J.W., Fehniger T.A. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica 2014, 2014:205796.
41. Shin D.-J., Park J.-Y., Jang Y.-Y., Lee J.-J., Lee Y.-K., Shin M.-G., Jung J.-Y., Carson W.E., Cho D., Kim S.-K. Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. Vet. Immunol. Immunopathol. 2013, 153:249-259.
42. Steel J.C., Waldmann T.A., Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 2012, 33:35-41.
43. Wu J. IL-15 agonists: the cancer cure cytokine. J. Mol. Genet. Med. 2013, 7:85.
44. Zambricki E., Shigeoka A., Kishimoto H., Sprent J., Burakoff S., Carpenter C., Milford E., McKay D. Signaling T-cell survival and death by IL-2 and IL-15. Am. J. Transplant. 2005, 5:2623-2631.
45. Zhang C., Zhang J., Niu J., Zhang J., Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008, 42:128-136.
46. Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., Bellucci R., Raderschall E., Canning C., Soiffer R.J. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579.